Nuvectis Pharma (NVCT) Non-Current Assets (2021)
Nuvectis Pharma (NVCT) posted Non-Current Assets of $824000.0 for Q4 2021.
Nuvectis Pharma (NVCT) Non-Current Assets (2021) Analysis & Trends
Nuvectis Pharma has reported Non-Current Assets for 1 years, with the latest figure at $824000.0 in Q4 2021.
- Quarterly Non-Current Assets changed N/A year-over-year to $824000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was $824000.0 (changed N/A YoY) and the FY2021 annual result came in at $824000.0, changed N/A from the prior year.
- Non-Current Assets held at $824000.0 in Q4 2021 per NVCT's latest filing.
- Over five years, Non-Current Assets peaked at $824000.0 in Q4 2021 and troughed at $824000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 824,000.00 |